Compare Stocks: CVAC, RLAY, LEGN, and VKTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVAC CureVac	$4.66	$4.66	$3.13 ▼ $5.72	$1.05B	1.77	992,546 shs	N/A
LEGN Legend Biotech	$21.75 -0.6%	$22.86	$16.24 ▼ $37.50	$4.24B	0.4	2.11 million shs	1.32 million shs
RLAY Relay Therapeutics	$19.01 +2.7%	$19.35	$3.86 ▼ $21.27	$4.06B	1.69	2.36 million shs	2.72 million shs
VKTX Viking Therapeutics	$33.98 +1.4%	$35.48	$22.96 ▼ $43.15	$3.91B	0.69	1.74 million shs	1.39 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVAC CureVac	0.00%	0.00%	0.00%	0.00%	-13.06%
LEGN Legend Biotech	-0.64%	+6.10%	+13.70%	-33.32%	-39.50%
RLAY Relay Therapeutics	+2.70%	-2.11%	-2.71%	+40.61%	+362.53%
VKTX Viking Therapeutics	+1.43%	+0.35%	+3.16%	+19.44%	+26.65%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVAC CureVac	$4.66	$4.66	$3.13 ▼ $5.72	$1.05B	1.77	992,546 shs	N/A
LEGN Legend Biotech	$21.75 -0.6%	$22.86	$16.24 ▼ $37.50	$4.24B	0.4	2.11 million shs	1.32 million shs
RLAY Relay Therapeutics	$19.01 +2.7%	$19.35	$3.86 ▼ $21.27	$4.06B	1.69	2.36 million shs	2.72 million shs
VKTX Viking Therapeutics	$33.98 +1.4%	$35.48	$22.96 ▼ $43.15	$3.91B	0.69	1.74 million shs	1.39 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVAC CureVac	0.00%	0.00%	0.00%	0.00%	-13.06%
LEGN Legend Biotech	-0.64%	+6.10%	+13.70%	-33.32%	-39.50%
RLAY Relay Therapeutics	+2.70%	-2.11%	-2.71%	+40.61%	+362.53%
VKTX Viking Therapeutics	+1.43%	+0.35%	+3.16%	+19.44%	+26.65%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CVAC CureVac	1.00	Sell	N/A	N/A
LEGN Legend Biotech	2.47	Hold	$52.29	140.39% Upside
RLAY Relay Therapeutics	2.93	Moderate Buy	$25.92	36.33% Upside
VKTX Viking Therapeutics	2.75	Moderate Buy	$96.63	184.36% Upside

Current Analyst Ratings Breakdown

Latest CVAC, RLAY, LEGN, and VKTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	LEGN Legend Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/20/2026	RLAY Relay Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/20/2026	RLAY Relay Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$28.00 ➝ $29.00
8/18/2026	LEGN Legend Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/18/2026	VKTX Viking Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/14/2026	RLAY Relay Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$28.00 ➝ $31.00
8/12/2026	LEGN Legend Biotech	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$48.00 ➝ $49.00
8/12/2026	LEGN Legend Biotech	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$75.00 ➝ $40.00
8/12/2026	LEGN Legend Biotech	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$80.00 ➝ $78.00
8/12/2026	LEGN Legend Biotech	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$29.00 ➝ $24.00
8/12/2026	LEGN Legend Biotech	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$59.00 ➝ $58.00

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CVAC CureVac	$70.74M	14.78	$0.99 per share	4.73	$3.36 per share	1.39
LEGN Legend Biotech	$1.03B	4.10	N/A	N/A	$6.35 per share	3.43
RLAY Relay Therapeutics	$15.35M	271.39	N/A	N/A	$4.06 per share	4.68
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$3.50 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CVAC CureVac	$175.50M	$0.72	6.47	N/A	N/A	199.92%	-23.03%	-19.09%	N/A
LEGN Legend Biotech	-$296.80M	-$0.25	N/A	18.59	N/A	-7.21%	-8.71%	-5.40%	11/11/2026 (Estimated)
RLAY Relay Therapeutics	-$276.48M	-$1.57	N/A	N/A	N/A	N/A	-42.27%	-38.67%	11/5/2026 (Estimated)
VKTX Viking Therapeutics	-$359.64M	-$4.66	N/A	N/A	N/A	N/A	-94.56%	-82.75%	10/28/2026 (Estimated)

Latest CVAC, RLAY, LEGN, and VKTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	LEGN Legend Biotech	$0.07	$0.09	+$0.02	$0.18	$355.96 million	$387.50 million
8/6/2026	Q2 2026	RLAY Relay Therapeutics	-$0.3911	-$0.41	-$0.0189	-$0.41	$0.96 million	$0.35 million
7/29/2026	Q2 2026	VKTX Viking Therapeutics	-$1.21	-$1.10	+$0.11	-$1.10	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CVAC CureVac	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CVAC CureVac	0.03	3.70	3.69
LEGN Legend Biotech	N/A	3.04	2.94
RLAY Relay Therapeutics	N/A	18.27	18.27
VKTX Viking Therapeutics	N/A	4.72	4.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CVAC CureVac	17.26%
LEGN Legend Biotech	70.89%
RLAY Relay Therapeutics	96.98%
VKTX Viking Therapeutics	76.03%

Insider Ownership

Company	Insider Ownership
CVAC CureVac	2.15%
LEGN Legend Biotech	0.02%
RLAY Relay Therapeutics	5.04%
VKTX Viking Therapeutics	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CVAC CureVac	880	224.34 million	219.52 million	No Data
LEGN Legend Biotech	2,965	193.77 million	193.73 million	Optionable
RLAY Relay Therapeutics	330	219.14 million	208.10 million	Optionable
VKTX Viking Therapeutics	20	116.65 million	110.47 million	Optionable

CVAC, RLAY, LEGN, and VKTX Headlines

Recent News About These Companies

3 Wall Street Analysts Think Viking Therapeutics Stock Will Roughly Triple Over the Next 12 Months. Here's Why I Think They're Wrong

September 3 at 7:57 PM | fool.com

Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know

September 3 at 7:57 PM | finance.yahoo.com

Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know

September 3 at 6:46 PM | zacks.com

Viking Therapeutics to Participate at Upcoming Investor Conferences

September 2 at 7:35 PM | finance.yahoo.com

Viking Therapeutics to Participate at Upcoming Investor Conferences

September 2 at 4:05 PM | prnewswire.com

Quantitative Investment Management LLC Invests $1.61 Million in Viking Therapeutics, Inc. $VKTX

September 1 at 6:07 AM | marketbeat.com

Bank of New York Mellon Corp Takes Position in Viking Therapeutics, Inc. $VKTX

September 1 at 3:35 AM | marketbeat.com

VKTX Stock Edges Higher In August Ahead Of Early-Stage Obesity-Drug Data Release In Q3

August 31, 2026 | stocktwits.comS

Viking Therapeutics Is Down 66% — Here’s What Could Bring It Back

August 31, 2026 | nai500.comN

Viking Therapeutics Is Down 66% — Here’s What Could Bring It Back

August 31, 2026 | nai500.comN

Viking Therapeutics, Inc. (NASDAQ:VKTX) Receives Average Rating of "Moderate Buy" from Analysts

August 31, 2026 | americanbankingnews.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Consensus Rating of "Moderate Buy" by Brokerages

August 31, 2026 | marketbeat.com

Viking Therapeutics Stock Is Down 66% From Its Peak. Here's What Comes Next.

August 30, 2026 | fool.com

Why Is Viking Therapeutics (VKTX) Up 2.3% Since Last Earnings Report?

August 30, 2026 | finance.yahoo.com

Why Is Viking Therapeutics (VKTX) Up 2.3% Since Last Earnings Report?

August 28, 2026 | zacks.com

Man Group plc Acquires Shares of 312,171 Viking Therapeutics, Inc. $VKTX

August 28, 2026 | marketbeat.com

Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough?

August 27, 2026 | fool.com

6,189,649 Shares in Viking Therapeutics, Inc. $VKTX Purchased by BlackRock Inc.

August 27, 2026 | marketbeat.com

Artia Global Partners LP Buys New Position in Viking Therapeutics, Inc. $VKTX

August 27, 2026 | marketbeat.com

Kintayl Capital LP Buys New Shares in Viking Therapeutics, Inc. $VKTX

August 26, 2026 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Invests $20.70 Million in Viking Therapeutics, Inc. $VKTX

August 26, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVAC, RLAY, LEGN, and VKTX Company Descriptions

CureVac NASDAQ:CVAC

$4.66 0.00 (0.00%)

As of 09/2/2026

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Legend Biotech NASDAQ:LEGN

$21.75 -0.14 (-0.64%)

As of 09/3/2026 04:00 PM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Relay Therapeutics NASDAQ:RLAY

$19.01 +0.50 (+2.70%)

As of 09/3/2026 04:00 PM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Viking Therapeutics NASDAQ:VKTX

$33.98 +0.48 (+1.43%)

As of 09/3/2026 04:00 PM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CVAC, RLAY, LEGN, and VKTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CVAC, RLAY, LEGN, and VKTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CVAC, RLAY, LEGN, and VKTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVAC, RLAY, LEGN, and VKTX Company Descriptions

CureVac NASDAQ:CVAC

Legend Biotech NASDAQ:LEGN

Relay Therapeutics NASDAQ:RLAY

Viking Therapeutics NASDAQ:VKTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CVAC, RLAY, LEGN, and VKTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CVAC, RLAY, LEGN, and VKTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CVAC, RLAY, LEGN, and VKTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVAC, RLAY, LEGN, and VKTX Company Descriptions

CureVac NASDAQ:CVAC

Legend Biotech NASDAQ:LEGN

Relay Therapeutics NASDAQ:RLAY

Viking Therapeutics NASDAQ:VKTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools